City

Clinical trials near Columbus, United States

Active studies with a listed research site in Columbus, United States.

28active studies

9recruiting now

24countries represented

140largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Obesity, OverweightCondition

aleniglipron, aleniglipronTreatment

United States74 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-09-01 · NCT07654374See eligibility →

Recruiting nowNot applicable

Anti-inflammatory Activities of Vitamin C Supplementation on the Gut Barrier Function in Adults With Obesity

Adequate Vitamin C Status, Inadequate Vitamin C StatusCondition

Vitamin C Supplement + Low Vitamin C Diet, Placebo + Low Vitamin C DietTreatment

United States1 locations

Ohio State UniversitySponsor

Updated 2026-09-01 · NCT07151105See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Obesity, OverweightCondition

Aleniglipron, PlaceboTreatment

United States71 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-08-10 · NCT07654361See eligibility →

Recruiting nowPhase 2

Atomoxetine in Melanocortin Obesity Syndrome

Melanocortin Obesity Syndrome, MCOSCondition

Atomoxetine, PlaceboTreatment

United States3 locations

Icahn School of Medicine at Mount SinaiSponsor

Updated 2026-08-07 · NCT06899178See eligibility →

Recruiting nowPhase 2

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

Breast Atypical Hyperplasia, Breast CarcinomaCondition

Biospecimen Collection, MammographyTreatment

United States3 locations

National Cancer Institute (NCI)Sponsor

Updated 2026-08-04 · NCT06195306See eligibility →

Recruiting nowNot applicable

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

Obesity & Overweight, Diabetes (DM)Condition

Glucagon-Like Peptide-1 Agonist (GLP-1)Treatment

United States1 locations

Ohio State UniversitySponsor

Updated 2026-07-24 · NCT07702461See eligibility →

Recruiting nowPhase 1

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

Overweight or Obese Adults, Overweight or Obese, Type 2 DiabetesCondition

ALV-100, PlaceboTreatment

United States2 locations

Alveus Therapeutics, Inc.Sponsor

Updated 2026-07-23 · NCT07399678See eligibility →

Recruiting nowNot applicable

Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss

Peripheral Artery Disease, Overweight or ObesityCondition

Weight loss, ExerciseTreatment

United States7 locations

Northwestern UniversitySponsor

Updated 2026-05-07 · NCT04228978See eligibility →

Recruiting nowNot applicable

Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention

Cardiometabolic Syndrome, Physical InactivityCondition

Black Impact InterventionTreatment

United States1 locations

Ohio State UniversitySponsor

Updated 2025-10-06 · NCT06055036See eligibility →

Opening soonPhase 3

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Treatment

Argentina, Brazil56 locations

Novo Nordisk A/SSponsor

Updated 2026-05-28 · NCT07282613See eligibility →

Active, not recruitingPhase 2

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

Overweight, Type 2 DiabetesCondition

Petrelintide, PlaceboTreatment

United States48 locations

Zealand PharmaSponsor

Updated 2026-08-21 · NCT06926842See eligibility →

Active, not recruitingPhase 3

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

Hypothalamic ObesityCondition

Setmelanotide, PlaceboTreatment

Canada, Germany28 locations

Rhythm Pharmaceuticals, Inc.Sponsor

Updated 2026-08-10 · NCT05774756See eligibility →

Active, not recruitingPhase 3

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

ObesityCondition

Semaglutide, PlaceboTreatment

Austria, Belgium56 locations

Novo Nordisk A/SSponsor

Updated 2026-08-07 · NCT05726227See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

ObesityCondition

Retatrutide, TirzepatideTreatment

Argentina, Germany65 locations

Eli Lilly and CompanySponsor

Updated 2026-07-20 · NCT06662383See eligibility →

Active, not recruitingPhase 3

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

Tirzepatide, PlaceboTreatment

Canada, Czechia33 locations

Eli Lilly and CompanySponsor

Updated 2026-06-29 · NCT06075667See eligibility →

Active, not recruitingNot applicable

A Dietary Intervention (Soy Soft Pretzels) for Reducing Chronic Inflammation in Obese Individuals

Colorectal Carcinoma, Obesity-Related Malignant NeoplasmCondition

Biospecimen Collection, Dietary InterventionTreatment

United States1 locations

Ohio State University Comprehensive Cancer CenterSponsor

Updated 2026-06-16 · NCT07650409See eligibility →

Active, not recruitingPhase 2

Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

Obese, ObesityCondition

Aleniglipron, PlaceboTreatment

United States16 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-04-27 · NCT07400588See eligibility →

Active, not recruitingNot applicable

Dietary Oils to Sustain Energy Study

Overweight and ObesityCondition

Soybean Oil Foods, Palm Oil FoodsTreatment

United States1 locations

Ohio State UniversitySponsor

Updated 2026-04-21 · NCT04975763See eligibility →

Active, not recruitingNot applicable

Functional Snack Foods With Safflower Oil and Soy in Postmenopausal Women Having Metabolic Syndrome

Metabolic Syndrome, OverweightCondition

wheat-safflower oil pretzels, soy-safflower oil pretzelsTreatment

United States1 locations

Ohio State UniversitySponsor

Updated 2026-04-20 · NCT02199054See eligibility →

Active, not recruitingPhase 2

Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)

ObesityCondition

NT-0796, PlaceboTreatment

United States9 locations

NodThera LimitedSponsor

Updated 2026-04-08 · NCT07220629See eligibility →

Active, not recruitingPhase 3

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Weight LossCondition

VK2735Treatment

Puerto Rico, United States127 locations

Viking Therapeutics, Inc.Sponsor

Updated 2026-04-07 · NCT07104383See eligibility →

Active, not recruitingPhase 4

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

ObesityCondition

Naltrexone-Bupropion (NB) Combination, PlaceboTreatment

United States140 locations

Currax PharmaceuticalsSponsor

Updated 2026-03-31 · NCT06098079See eligibility →

Active, not recruitingNot applicable

Feasibility and Acceptability of Incorporating Smartwatches Into an Exercise is Medicine Program in Older Individuals

Physical Inactivity, ObesityCondition

EIM+Treatment

United States1 locations

Ohio State UniversitySponsor

Updated 2025-12-05 · NCT06287255See eligibility →

Active, not recruitingPhase 3

VK2735 for Weight Management Phase 3

Weight LossCondition

VK2735Treatment

Puerto Rico, United States137 locations

Viking Therapeutics, Inc.Sponsor

Updated 2025-11-24 · NCT07104500See eligibility →

Active, not recruitingNot applicable

Respiratory Effects of E-Cigarettes in Obese Youth

E-Cig UseCondition

ECIG own, ECIG VuseTreatment

United States1 locations

Ohio State University Comprehensive Cancer CenterSponsor

Updated 2025-10-20 · NCT05869318See eligibility →

Active, not recruitingNot applicable

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

Cardiovascular Kidney Metabolic SyndromeCondition

Intervention, Active ComparatorTreatment

United States1 locations

Ohio State UniversitySponsor

Updated 2025-09-23 · NCT07188545See eligibility →

Active, not recruitingPhase 4

The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans

PreDiabetes, Impaired Glucose ToleranceCondition

Sacubitril-Valsartan Tab 97-103 MG, Valsartan 160mgTreatment

United States1 locations

Ohio State UniversitySponsor

Updated 2025-08-11 · NCT03938389See eligibility →

Active, not recruitingNot applicable

Clinical Investigation of the da Vinci Surgical System

Thymoma, Mediastinal TumorCondition

Robotic-assisted SurgeryTreatment

United States4 locations

Intuitive SurgicalSponsor

Updated 2024-06-03 · NCT05682742See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Columbus, United States

Current studies

Related cities